Kerry Reynolds

Dr. Kerry Reynolds, Clinical Director of Inpatient Oncology at Massachusetts General Hospital, discusses immune checkpoint inhibitors and their role in cancer treatment. They explore the types of tumors eligible for these inhibitors, the management of adverse events, and the importance of cortisol replacement before thyroid replacement in central hypopositis. The speakers also explain the significance of Tumor Proportion Score as a biomarker for predicting response to immune checkpoint inhibitors.